TABLE 3.

Contribution of anti-CD4-BS antibodies to the cross-neutralizing activity of plasmasa

Subject (% breadth)IsolatePlasma% Neutralization of flowthroughIC50 (μg/ml) of eluted antibodies
WT gp120BS gp120WT gp120BS gp120
VC10042 (100)YU2100(-)1001.2(-)
QH069290191001.9(-)
TORNO9215906.6(-)
JRFL9910991.5(-)
VC10014 (79)YU292(-)156.58.1
QH069252122814.519.1
TORNO70254512.314.6
JRFL955357.310.3
CC1161 (84)YU28937651.4(-)
QH06927344626.1(-)
TORNO9582811.83.8
JRFL9888893.91.8
VC10002 (32)YU240(-)(-)(-)(-)
QH06928553607.210.8
TORNO7252578.915
JRFL9047558.613.4
CC1508 (95)YU2959192(-)(-)
QH069298687513.614.2
TORNO9082868.113.4
JRFL10010099(-)(-)
VC20013 (63)YU2271222(-)(-)
QH0692787872(-)(-)
TORNO737372(-)(-)
JRFL7063588.49.7
VC20011 (5)YU2(-)(-)(-)(-)(-)
QH0692(-)(-)(-)(-)(-)
TORNO(-)(-)(-)(-)(-)
JRFL(-)(-)(-)(-)(-)
  • a The anti-HIV-neutralizing activities of the flowthrough from the WT gp120 and the CD4-BS mutant gp120 (BS gp120) and those of the antibodies eluted from the WT gp120 and CD4-BS mutant gp120 were determined as discussed in Materials and Methods. For the plasma and flowthroughs, the percent neutralization at a 1:50 dilution is shown. Significant neutralization (≥50%) is shown in boldface. For the eluted antibodies, the IC50s are shown. (-), neutralizing activity (50% neutralization) against the indicated virus was not recorded at a 1:50 dilution. The overall breadth of neutralization for each plasma is shown under each code identifier.